米哚妥林在晚期系统性肥大细胞增多症患者日常临床实践中的应用
该研究基于德国嗜酸性粒细胞与肥大细胞疾病登记处79例晚期系统性肥大细胞增多症患者,评估米哚妥林起始剂量200 mg/日与≤150 mg/日的方案、安全性、疗效及总生存。结果显示缓解率分别为60%(改良Valent标准)、29%(IWG-MRT-ECNM标准)和13%(纯病理缓解标准),缓解持续时间与总生存改善相关(p < 0.001),停药后7/41(17%)出现停药综合征,后续通过剂量递减和糖皮质激素桥接有效预防。
要点
- 米哚妥林起始200 mg/日者63/79(80%),≤150 mg/日者16/79(20%);第12个月仍持续用药分别为44/63(70%)和10/16(63%)。
- 改良Valent标准缓解率60%,IWG-MRT-ECNM标准29%,纯病理缓解标准13%。
- 前12个月内,除改良Valent标准外,缓解达成与剂量无关;缓解持续时间(改良Valent/IWG-MRT-ECNM标准)与总生存改善相关(p < 0.001)。
核心结论
- 米哚妥林在晚期系统性肥大细胞增多症患者中表现出良好的安全性,并在不同给药方案下产生持久缓解。
研究设计与样本
- 研究纳入德国嗜酸性粒细胞与肥大细胞疾病登记处79例晚期系统性肥大细胞增多症患者,评估米哚妥林给药方案、安全性、疗效及总生存。
主要发现
- 米哚妥林起始剂量200 mg/日者63/79(80%),≤150 mg/日者16/79(20%);第12个月继续用药者分别为44/63(70%)和10/16(63%)。
- 累计观察146患者年期间,96例不良事件导致剂量调整,最常见为恶心/呕吐(n = 22,23%)和中性粒细胞减少(n = 8,8%)。
- 缓解率分别为60%(改良Valent标准)、29%(IWG-MRT-ECNM标准)和13%(纯病理缓解标准)。
- 前12个月内,除改良Valent标准外,缓解达成与剂量无关;缓解持续时间(改良Valent/IWG-MRT-ECNM标准)与总生存改善相关(p < 0.001)。
- 因缺乏缓解/进展、死亡和不良事件而最终停用米哚妥林者分别为28例(39%)、5例(6%)和13例(17%);停药后7/41(17%)患者出现停药综合征,后续患者通过剂量递减和糖皮质激素桥接有效预防。
关键数值与推荐
- 改良Valent标准缓解率60%,IWG-MRT-ECNM标准缓解率29%,纯病理缓解标准缓解率13%。
- 前12个月内,除改良Valent标准外,缓解达成与剂量无关。
- 缓解持续时间(改良Valent/IWG-MRT-ECNM标准)与总生存改善相关(p < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Midostaurin, a multikinase/KIT inhibitor, is approved for the treatment of advanced systemic mastocytosis (AdvSM). We evaluated dosing regimens, safety, efficacy and overall survival (OS) of 79 patients from the 'German Registry on Disorders of Eosinophils and Mast Cells'. Midostaurin was initiated at 200 and ≤150 mg daily in 63/79 (80%) and 16/79 (20%) and continued at month 12 in 44/63 (70%) and 10/16 (63%) patients respectively. Over a cumulative observation period of 146 patient-years, 96 adverse events (AE) led to dose adjustment, most commonly nausea/emesis (n = 22, 23%) and neutropenia (n = 8, 8%). Responses were achieved in 60% (modified Valent criteria), 29% (IWG-MRT-ECNM, International Working Group-Myeloproliferative Neoplasms Research and Treatment & ECNM criteria) and 13% (pure pathological response criteria) of patients. Within the first 12 months, achievement of a response was dose independent except for modified Valent criteria. The response duration (modified Valent/IWG-MRT-ECNM criteria) correlated with improved OS (p < 0.001). Midostaurin was ultimately stopped in patients due to lack of response/progression, death and AEs in 28 (39%), 5 (6%) and 13 (17%) patients respectively. Following midostaurin discontinuation, 7/41 (17%) patients experienced a discontinuation syndrome, which was effectively prevented in subsequent patients through dose tapering and corticosteroid bridging. In conclusion, midostaurin demonstrated a favourable safety profile and yielded durable responses in AdvSM patients across dosing regimens.
引用
- Lübke J, Naumann N, Brand T, et al. Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis. Br J Haematol. 2025. PMID: 40781766. doi:10.1111/bjh.70065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。